Latest Information Update: 21 Nov 2006
At a glance
- Originator NeurogesX
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 21 Nov 2006 Discontinued - Phase-I for Pain in USA (unspecified route)
- 16 Jan 2003 Phase-I clinical trials in Pain in USA (unspecified route)
- 11 Mar 2002 Preclinical trials in Pain in USA (unspecified route)